跳至主要内容
临床试验/NCT03893526
NCT03893526已完成4 期

The Effect of Neprilysin on Plasma Concentrations of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

University of Copenhagen1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2019年1月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Blood Glucose

研究概览

简要总结

Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown.

We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2 diabetes during a standardized meal and measured plasma concentrations of GLP-1

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Type 2 Diabetes
  • Oral Antidiabetics Medicine Only
  • Body Mass Index of 25-35
  • Type 2 Diabetes

排除标准

  • acute diseases within the two weeks
  • chronic diseases
  • alcoholism, drug addiction or recent weight loss
  • blood donation within the last 3 months

研究组 & 干预措施

Placebo

Placebo Comparator

Participants are subjected to a standardized meal

干预措施: Placebo (Drug)

Entrestro

Active Comparator

194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal

干预措施: Entresto (Drug)

Sitagliptin

Active Comparator

200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal

干预措施: Sitagliptin (Drug)

Entrestro + sitagliptin

Active Comparator

194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal

干预措施: Entresto (Drug)

Entrestro + sitagliptin

Active Comparator

194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal

干预措施: Sitagliptin (Drug)

Valsartan

Active Comparator

206mg valsartan as one single dose followed by a standardized meal

干预措施: Valsartan (Drug)

结局指标

主要结局

Blood Glucose

时间窗: 3 hours after treatment ( during the subsequent standardized meal)

Plasma Concentrations of glucose

次要结局

  • Plasma Concentrations of Glucagon(3 hours after treatment ( during the subsequent standardized meal))
  • Plasma Concentrations of Insulin(3 hours after treatment ( during the subsequent standardized meal))
  • Plasma Concentrations of GLP-1(3 hours after treatment ( during the subsequent standardized meal))
  • Plasma Concentrations of GIP(3 hours after treatment ( during the subsequent standardized meal))
  • Plasma Concentrations of C-Peptide(3 hours after treatment ( during the subsequent standardized meal))
  • Plasma Concentrations of Amino Acids(3 hours after treatment ( during the subsequent standardized meal))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nicolai Jacob Wewer Albrechtsen

Resident

University of Copenhagen

研究点 (1)

Loading locations...

相似试验